DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT CHRONIC MYELOID LEUKEMIA IN ACCELERATED PHASE: 24-MONTH DATA FROM START-A

被引：0
|
作者：
Rea, D. [1 ]
Dombret, H. [1 ]
Kim, D. W. [2 ]
Rosti, G. [3 ]
Roy, L. [4 ]
Garzon, F. T. [5 ]
Yuan, X. [5 ]
Cortes, J. [6 ]
Guilhot, F. [4 ]
机构：
[1] Hop St Louis, Paris, France
[2] Catholic Univ, St Marys Hosp, Seoul, South Korea
[3] Bologna Univ Hosp, Inst Seragnoli, Bologna, Italy
[4] CHU Poitiers, Poitiers, France
[5] Bristol Myers Squibb Co, Wallingford, CT USA
[6] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0982
引用
收藏
页码：391 / 391
页数：1
相关论文
共 50 条
  • [31] Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
    Chuah, Charles
    Melo, Junia V.
    ONCOTARGETS AND THERAPY, 2009, 2 : 83 - 94
  • [32] QUALITY OF LIFE AND SYMPTOM PROFILE IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA
    Ionova, I.
    Nikitina, T.
    Gritsenko, T.
    Ivanova, V.
    Kuchma, G.
    Fedorenko, D.
    Kurbatova, K.
    HAEMATOLOGICA, 2012, 97 : 314 - 314
  • [33] Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program
    Ganibacoiti, Carlo
    CorteS, Jorge
    Kim, Dong-Wook
    Dombret, Herve
    Zhu, Chao
    Van Tornout, Jan M. A.
    Garzon, Felix T.
    Baccarani, Michele
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [34] Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data
    Kantarjian, Hagop M.
    Jabbour, Elias
    Giles, Francis J.
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Wang, Jim
    Woodman, Richard C.
    Baccarani, Michele
    le Coutre, Philipp D.
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1278 - 1279
  • [35] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, F. J.
    le Coutre, P. D.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Radich, J. P.
    Saglio, G.
    Hughes, T. P.
    Martinelli, G.
    Kim, D-W
    Novick, S.
    Gillis, K.
    Fan, X.
    Cortes, J.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (01) : 107 - 112
  • [36] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    P D le Coutre
    J Pinilla-Ibarz
    R A Larson
    N Gattermann
    O G Ottmann
    A Hochhaus
    J P Radich
    G Saglio
    T P Hughes
    G Martinelli
    D-W Kim
    S Novick
    K Gillis
    X Fan
    J Cortes
    M Baccarani
    H M Kantarjian
    Leukemia, 2013, 27 : 107 - 112
  • [37] Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
    Smith, B. Douglas
    Rosti, Gianantonio
    Bruemmendorf, Tim
    Roboz, Gail
    Gambacorti-Passerini, Carlo
    Charbonnier, Aude
    Viqueira, Andrea
    Leip, Eric
    Giles, Frank
    Ernst, Thomas
    Castagnetti, Frank
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S240 - S240
  • [38] Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
    Smith, B. Douglas
    Bruemmendorf, Tim H.
    Roboz, Gail J.
    Gambacorti-Passerini, Carlo
    Charbonnier, Aude
    Viquiera, Andrea
    Leip, Eric
    Giles, Frank
    Ernst, Thomas
    Hochhaus, Andreas
    Rosti, Gianantonio
    BLOOD, 2019, 134
  • [39] Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
    Zackova, Daniela
    Klamova, Hana
    Belohlavkova, Petra
    Stejskal, Lukas
    Necasova, Tereza
    Semerad, Lukas
    Weinbergerova, Barbora
    Srbova, Dana
    Voglova, Jaroslava
    Cicatkova, Petra
    Sustkova, Zuzana
    Hornak, Tomas
    Baranova, Jana
    Prochazkova, Jirina
    Mayer, Jiri
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 194 - 202
  • [40] Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    Shah, Neil P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Rea, Delphine
    Dorlhiac-Llacer, Pedro E.
    Milone, Jorge H.
    Vela-Ojeda, Jorge
    Silver, Richard T.
    Khoury, H. Jean
    Charbonnier, Aude
    Khoroshko, Nina
    Paquette, Ronald L.
    Deininger, Michael
    Collins, Robert H.
    Otero, Irma
    Hughes, Timothy
    Bleickardt, Eric
    Strauss, Lewis
    Francis, Stephen
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3204 - 3212
12345